Difference between revisions of "Anaplastic large cell lymphoma, pediatric"
Jump to navigation
Jump to search
Warner-admin (talk | contribs) m (Text replacement - "{| class="wikitable" style="float:right; margin-left: 5px;" |- |back to top |}" to "") |
m |
||
| Line 26: | Line 26: | ||
|} | |} | ||
''Note: there appear to be several dosing errors in Table 2; the authors have been contacted for clarification.'' | ''Note: there appear to be several dosing errors in Table 2; the authors have been contacted for clarification.'' | ||
| − | ====Chemotherapy, | + | ====Chemotherapy, prephase==== |
*[[Cyclophosphamide (Cytoxan)]] 200 mg/m<sup>2</sup> IV once per day on days 1 & 2 | *[[Cyclophosphamide (Cytoxan)]] 200 mg/m<sup>2</sup> IV once per day on days 1 & 2 | ||
| + | ====Glucocorticoid therapy, prephase==== | ||
*[[Dexamethasone (Decadron)]] 5 mg/m<sup>2</sup>/day PO on days 1 & 2, then 10 mg/m<sup>2</sup>/day PO on days 3 to 5 | *[[Dexamethasone (Decadron)]] 5 mg/m<sup>2</sup>/day PO on days 1 & 2, then 10 mg/m<sup>2</sup>/day PO on days 3 to 5 | ||
====CNS prophylaxis==== | ====CNS prophylaxis==== | ||
| Line 36: | Line 37: | ||
====Chemotherapy, induction==== | ====Chemotherapy, induction==== | ||
*[[Methotrexate (MTX)]] 3000 mg/m<sup>2</sup> IV over 3 hours once on day 1 | *[[Methotrexate (MTX)]] 3000 mg/m<sup>2</sup> IV over 3 hours once on day 1 | ||
| − | |||
*[[Ifosfamide (Ifex)]] as follows: | *[[Ifosfamide (Ifex)]] as follows: | ||
**Cycles 1, 3, 5: 800 mg/m<sup>2</sup> IV once per day on days 1 to 5 | **Cycles 1, 3, 5: 800 mg/m<sup>2</sup> IV once per day on days 1 to 5 | ||
| Line 47: | Line 47: | ||
*[[Doxorubicin (Adriamycin)]] as follows: | *[[Doxorubicin (Adriamycin)]] as follows: | ||
**Cycles 2, 4, 6: 25 mg/m<sup>2</sup> IV once per day on days 4 & 5 | **Cycles 2, 4, 6: 25 mg/m<sup>2</sup> IV once per day on days 4 & 5 | ||
| + | |||
| + | ====Glucocorticoid therapy, induction==== | ||
| + | *[[Dexamethasone (Decadron)]] 10 mg/m<sup>2</sup>/day PO on days 1 to 5 | ||
| + | |||
'''21-day cycle for 6 cycles''' | '''21-day cycle for 6 cycles''' | ||
===References=== | ===References=== | ||
| Line 70: | Line 74: | ||
|} | |} | ||
''Note: the intrathecal component is only described as "triple therapy" in the manuscript.'' | ''Note: the intrathecal component is only described as "triple therapy" in the manuscript.'' | ||
| − | ====Chemotherapy, | + | ====Chemotherapy, prephase==== |
*[[Cyclophosphamide (Cytoxan)]] 200 mg/m<sup>2</sup> IV once per day on days 1 & 2 | *[[Cyclophosphamide (Cytoxan)]] 200 mg/m<sup>2</sup> IV once per day on days 1 & 2 | ||
| + | ====Glucocorticoid therapy, prephase==== | ||
*[[Dexamethasone (Decadron)]] 5 mg/m<sup>2</sup>/day PO on days 1 & 2, then 10 mg/m<sup>2</sup>/day PO on days 3 to 5 | *[[Dexamethasone (Decadron)]] 5 mg/m<sup>2</sup>/day PO on days 1 & 2, then 10 mg/m<sup>2</sup>/day PO on days 3 to 5 | ||
====CNS prophylaxis==== | ====CNS prophylaxis==== | ||
| Line 82: | Line 87: | ||
====Chemotherapy, induction==== | ====Chemotherapy, induction==== | ||
*[[Methotrexate (MTX)]] 3000 mg/m<sup>2</sup> IV over 3 hours once on day 1 | *[[Methotrexate (MTX)]] 3000 mg/m<sup>2</sup> IV over 3 hours once on day 1 | ||
| − | |||
*[[Ifosfamide (Ifex)]] as follows: | *[[Ifosfamide (Ifex)]] as follows: | ||
**Cycles 1, 3, 5: 800 mg/m<sup>2</sup> IV once per day on days 1 to 5 | **Cycles 1, 3, 5: 800 mg/m<sup>2</sup> IV once per day on days 1 to 5 | ||
| Line 93: | Line 97: | ||
*[[Doxorubicin (Adriamycin)]] as follows: | *[[Doxorubicin (Adriamycin)]] as follows: | ||
**Cycles 2, 4, 6: 25 mg/m<sup>2</sup> IV once per day on days 4 & 5 | **Cycles 2, 4, 6: 25 mg/m<sup>2</sup> IV once per day on days 4 & 5 | ||
| + | |||
| + | ====Glucocorticoid therapy, induction==== | ||
| + | *[[Dexamethasone (Decadron)]] 10 mg/m<sup>2</sup>/day PO on days 1 to 5 | ||
| + | |||
'''21-day cycle for 6 cycles''' | '''21-day cycle for 6 cycles''' | ||
===References=== | ===References=== | ||
Revision as of 19:54, 11 August 2022
Section editor transclusions This page contains studies that were specific to pediatric populations. For the more general ALCL page, follow this link.
3 regimens on this page
5 variants on this page
|
Untreated
COG ANHL12P1 protocol
Protocol
| Study | Years of enrollment | Evidence |
|---|---|---|
| Lowe et al. 2021 (COG ANHL12P1) | 2013-2017 | Randomized Phase 2 |
Note: there appear to be several dosing errors in Table 2; the authors have been contacted for clarification.
Chemotherapy, prephase
- Cyclophosphamide (Cytoxan) 200 mg/m2 IV once per day on days 1 & 2
Glucocorticoid therapy, prephase
- Dexamethasone (Decadron) 5 mg/m2/day PO on days 1 & 2, then 10 mg/m2/day PO on days 3 to 5
CNS prophylaxis
- Methotrexate (MTX) age-based IT once on day 1
5-day course
Antibody-drug conjugate therapy, induction
- Brentuximab vedotin (Adcetris) 1.8 mg/kg (maximum dose of 180 mg) IV over 30 minutes once on day 1
Chemotherapy, induction
- Methotrexate (MTX) 3000 mg/m2 IV over 3 hours once on day 1
- Ifosfamide (Ifex) as follows:
- Cycles 1, 3, 5: 800 mg/m2 IV once per day on days 1 to 5
- Etoposide (Vepesid) as follows:
- Cycles 1, 3, 5: 100 mg/m2 IV once per day on days 4 & 5
- Cytarabine (Ara-C) as follows:
- Cycles 1, 3, 5: 150 mg/m2 IV every 12 hours on days 4 & 5 (total dose per cycle: 600 mg/m2)
- Cyclophosphamide (Cytoxan) as follows:
- Cycles 2, 4, 6: 200 mg/m2 IV once per day on days 1 to 5
- Doxorubicin (Adriamycin) as follows:
- Cycles 2, 4, 6: 25 mg/m2 IV once per day on days 4 & 5
Glucocorticoid therapy, induction
- Dexamethasone (Decadron) 10 mg/m2/day PO on days 1 to 5
21-day cycle for 6 cycles
References
- COG ANHL12P1: Lowe EJ, Reilly AF, Lim MS, Gross TG, Saguilig L, Barkauskas DA, Wu R, Alexander S, Bollard CM. Brentuximab vedotin in combination with chemotherapy for pediatric patients with ALK+ ALCL: results of COG trial ANHL12P1. Blood. 2021 Jul 1;137(26):3595-3603. link to original article contains verified protocol PubMed NCT01979536
EICNHL ALCL99 protocol
Protocol
| Study | Years of enrollment | Evidence | Comparator | Comparative Efficacy | Comparative Toxicity |
|---|---|---|---|---|---|
| Brugières et al. 2009 (EICNHL ALCL99) | 1999-2005 | Randomized (E-switch-ic) | EICHNL ALCL99; alternate MTX dosing | Inconclusive whether non-inferior EFS | Less toxic |
Note: the intrathecal component is only described as "triple therapy" in the manuscript.
Chemotherapy, prephase
- Cyclophosphamide (Cytoxan) 200 mg/m2 IV once per day on days 1 & 2
Glucocorticoid therapy, prephase
- Dexamethasone (Decadron) 5 mg/m2/day PO on days 1 & 2, then 10 mg/m2/day PO on days 3 to 5
CNS prophylaxis
- Methotrexate (MTX) (dose not specified) IT once on day 1
- Cytarabine (Ara-C) (dose not specified) IT once on day 1
- Hydrocortisone (Cortef) (dose not specified) IT once on day 1
5-day course
Chemotherapy, induction
- Methotrexate (MTX) 3000 mg/m2 IV over 3 hours once on day 1
- Ifosfamide (Ifex) as follows:
- Cycles 1, 3, 5: 800 mg/m2 IV once per day on days 1 to 5
- Etoposide (Vepesid) as follows:
- Cycles 1, 3, 5: 100 mg/m2 IV once per day on days 4 & 5
- Cytarabine (Ara-C) as follows:
- Cycles 1, 3, 5: 150 mg/m2 IV every 12 hours on days 4 & 5 (total dose per cycle: 600 mg/m2)
- Cyclophosphamide (Cytoxan) as follows:
- Cycles 2, 4, 6: 200 mg/m2 IV once per day on days 1 to 5
- Doxorubicin (Adriamycin) as follows:
- Cycles 2, 4, 6: 25 mg/m2 IV once per day on days 4 & 5
Glucocorticoid therapy, induction
- Dexamethasone (Decadron) 10 mg/m2/day PO on days 1 to 5
21-day cycle for 6 cycles
References
- EICNHL ALCL99: Brugières L, Le Deley MC, Rosolen A, Williams D, Horibe K, Wrobel G, Mann G, Zsiros J, Uyttebroeck A, Marky I, Lamant L, Reiter A. Impact of the methotrexate administration dose on the need for intrathecal treatment in children and adolescents with anaplastic large-cell lymphoma: results of a randomized trial of the EICNHL Group. J Clin Oncol. 2009 Feb 20;27(6):897-903. Epub 2009 Jan 12. link to original article contains verified protocol PubMed NCT00006455
APO
APO: Adriamycin (Doxorubicin), Prednisone, Oncovin (Vincristine)
HOP: Hydroxydaunorubicin (Doxorubicin), Oncovin (Vincristine), Prednisone
Regimen
| Study | Years of enrollment | Evidence |
|---|---|---|
| Alexander et al. 2014 (COG ANHL0131) | 2004-2008 | Non-randomized portion of phase III RCT |
Chemotherapy
- Doxorubicin (Adriamycin) 75 mg/m2 IV once per day on days 1 & 22
- Prednisone (Sterapred) 40 mg/m2/day PO on days 1 to 28
- Vincristine (Oncovin) 1.5 mg/m2 (maximum dose of 2 mg) IV once per day on days 1, 8, 15, 22, 29
CNS prophylaxis
- Methotrexate (MTX) age-adjusted IT once per day on days 1, 8, 22
6-week course
Subsequent treatment
- APO versus APV maintenance
References
- COG ANHL0131: Alexander S, Kraveka JM, Weitzman S, Lowe E, Smith L, Lynch JC, Chang M, Kinney MC, Perkins SL, Laver J, Gross TG, Weinstein H. Advanced stage anaplastic large cell lymphoma in children and adolescents: results of ANHL0131, a randomized phase III trial of APO versus a modified regimen with vinblastine: a report from the children's oncology group. Pediatr Blood Cancer. 2014 Dec;61(12):2236-42. Epub 2014 Aug 23. link to original article link to PMC article contains verified protocol PubMed NCT00059839
Relapsed or refractory, subsequent lines of therapy
Crizotinib monotherapy
Regimen
| FDA-recommended dose |
| Study | Years of enrollment | Evidence |
|---|---|---|
| Mossé et al. 2013 (COG ADVL0912) | 2009-2012 | Phase 1/2 (RT) |
Note: this was an expansion cohort of a phase 1/2 study.
Biomarker eligibility criteria
- ALK rearrangement
Targeted therapy
- Crizotinib (Xalkori) 280 mg/m2 PO twice per day
28-day cycles
References
- COG ADVL0912: Mossé YP, Lim MS, Voss SD, Wilner K, Ruffner K, Laliberte J, Rolland D, Balis FM, Maris JM, Weigel BJ, Ingle AM, Ahern C, Adamson PC, Blaney SM. Safety and activity of crizotinib for paediatric patients with refractory solid tumours or anaplastic large-cell lymphoma: a Children's Oncology Group phase 1 consortium study. Lancet Oncol. 2013 May;14(6):472-80. Epub 2013 Apr 16. link to original article link to PMC article contains verified protocol PubMed NCT00939770